Magenta Therapeutics, Inc. – NASDAQ:MGTA
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Magenta Therapeutics stock price monthly change
-13.04%
month
Magenta Therapeutics stock price quarterly change
+9.38%
quarter
Magenta Therapeutics stock price yearly change
-63.73%
year
Magenta Therapeutics key metrics
Market Cap | 42.44M |
Enterprise value | 18.71M |
P/E | -0.62 |
EV/Sales | N/A |
EV/EBITDA | -0.16 |
Price/Sales | N/A |
Price/Book | 0.43 |
PEG ratio | 1.46 |
EPS | -20.4 |
Revenue | N/A |
EBITDA | -36.26M |
Income | -67.32M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMagenta Therapeutics stock price history
Magenta Therapeutics stock forecast
Magenta Therapeutics financial statements
| Dec 2022 | 0 | -23.06M | |
|---|---|---|---|
| Mar 2023 | 0 | -26.21M | |
| Jun 2023 | 0 | -3.28M | |
| Sep 2023 | 0 | -14.76M |
| 2023-08-03 | 0.19 | -0.29 |
|---|
| Dec 2022 | 146645000 | 40.68M | 27.75% |
|---|---|---|---|
| Mar 2023 | 83441000 | 5.98M | 7.17% |
| Jun 2023 | 78638000 | 4.03M | 5.13% |
| Sep 2023 | 192462000 | 14.08M | 7.32% |
| Sep 2022 | -13.80M | 15.24M | 2.76M |
|---|---|---|---|
| Dec 2022 | -16.68M | 15.22M | 66K |
| Mar 2023 | -35.59M | 26.49M | 0 |
| Jun 2023 | -6.54M | 18.87M | 49.70M |
Magenta Therapeutics alternative data
| Aug 2023 | 67 |
|---|---|
| Sep 2023 | 67 |
| Oct 2023 | 67 |
| Nov 2023 | 67 |
| Dec 2023 | 67 |
| Jan 2024 | 67 |
| Feb 2024 | 67 |
| Mar 2024 | 67 |
| Apr 2024 | 67 |
| May 2024 | 67 |
| Jun 2024 | 67 |
| Jul 2024 | 67 |
Magenta Therapeutics other data
80.98%
+5.24%
of MGTA is owned by hedge funds
44.49M
+128.71K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2023 | 0 | 3700000 |
| Sep 2023 | 112924 | 0 |
| Patent |
|---|
Application Filling date: 3 Dec 2021 Issue date: 1 Sep 2022 |
Application Filling date: 22 Oct 2021 Issue date: 25 Aug 2022 |
Application Filling date: 3 Dec 2021 Issue date: 11 Aug 2022 |
Application Filling date: 21 Oct 2021 Issue date: 21 Jul 2022 |
Application Filling date: 22 Oct 2021 Issue date: 9 Jun 2022 |
Application Filling date: 22 Oct 2021 Issue date: 9 Jun 2022 |
Application Filling date: 22 Oct 2021 Issue date: 9 Jun 2022 |
Application Filling date: 7 May 2021 Issue date: 31 Mar 2022 |
Application Filling date: 6 Jul 2021 Issue date: 3 Mar 2022 |
Grant Filling date: 13 Mar 2019 Issue date: 1 Mar 2022 |
-
When is Magenta Therapeutics's next earnings date?
Unfortunately, Magenta Therapeutics's (MGTA) next earnings date is currently unknown.
-
Does Magenta Therapeutics pay dividends?
No, Magenta Therapeutics does not pay dividends.
-
How much money does Magenta Therapeutics make?
Magenta Therapeutics has a market capitalization of 42.44M. Magenta Therapeutics made a loss 72.02M US dollars in net income (profit) last year or -$0.29 on an earnings per share basis.
-
What is Magenta Therapeutics's stock symbol?
Magenta Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "MGTA".
-
What is Magenta Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Magenta Therapeutics?
Shares of Magenta Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Magenta Therapeutics's key executives?
Magenta Therapeutics's management team includes the following people:
- Dr. Jason Gardner Ph.D. Co-Founder, Chief Executive Officer, Pres & Director(age: 54, pay: $793,260)
- Mr. Stephen F. Mahoney J.D., MBA Chief Financial & Operating Officer and Treasurer(age: 54, pay: $420,480)
-
Is Magenta Therapeutics founder-led company?
Yes, Magenta Therapeutics is a company led by its founder Dr. Jason Gardner Ph.D..
-
How many employees does Magenta Therapeutics have?
As Jul 2024, Magenta Therapeutics employs 67 workers.
-
When Magenta Therapeutics went public?
Magenta Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 21 Jun 2018.
-
What is Magenta Therapeutics's official website?
The official website for Magenta Therapeutics is magentatx.com.
-
Where are Magenta Therapeutics's headquarters?
Magenta Therapeutics is headquartered at 100 Technology Square, Cambridge, MA.
-
How can i contact Magenta Therapeutics?
Magenta Therapeutics's mailing address is 100 Technology Square, Cambridge, MA and company can be reached via phone at 857 242 0170.
Magenta Therapeutics company profile:
Magenta Therapeutics, Inc.
magentatx.comExchange:
NASDAQ
Full time employees:
67
Industry:
Biotechnology
Sector:
Healthcare
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
100 Technology Square
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001690585
ISIN: US55910K1088
CUSIP: 55910K108
